// App-Quantinova.ai

: PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Nicholas J. Vogelzang

  • A. Oliver Sartor

  • Alison A. Armour

  • Richard Adam Messmann

  • Michael Groaning

  • Adam Robarts

  • Anthony W. Tolcher

  • Michael S. Gordon

  • Hani M. Babiker

  • Phillip Kuo

  • Megan Kearney

  • Adam Jendrisak

  • Yipeng Wang

  • Mark Andrew Landers

  • Daniel Peter Petrylak

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Tulane University School of Medicine, New Orleans, LA

  • Endocyte Inc, Indianapolis, IN

  • ProNAi Therapeutics Inc, Plymouth, MI

  • Endocyte, West Lafayette, IN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • START, San Antonio, TX

  • Pinnacle Oncology Hematology, Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program, Virginia G. Piper Cancer Center, Scottsdale, AZ

  • University of Arizona Cancer Center, Tucson, AZ

  • University of Arizona, Tucson, AZ

  • Epic Sciences, Inc., San Diego, CA

  • Yale University School of Medicine, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Folate Hydrolase 1

Drug/Treatment

  • EC0652

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02202447

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved